U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07200375) titled 'An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma' on Sept. 23.
Brief Summary: This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Study Start Date: Sept. 22
Study Type: OBSERVATIONAL
Condition:
Diffuse Large B-Cell Lymphoma
Intervention:
DRUG: Glofitamab
Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.
Recruitment Status: NOT_Y...